Morgan Stanley reiterates Overweight on Gilead stock after Arcellx deal
📚 Related People & Topics
Morgan Stanley
American financial services company
Morgan Stanley is an American multinational investment bank and financial services company headquartered at 1585 Broadway in Midtown Manhattan, New York City. With offices in 42 countries and more than 80,000 employees, the firm's clients include corporations, governments, institutions, and individu...
Entity Intersection Graph
Connections for Morgan Stanley:
🌐
Artificial intelligence
2 shared
🏢
Vital Farms
1 shared
🌐
March
1 shared
🏢
Nvidia
1 shared
🏢
Gilead Sciences
1 shared
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Dystopian AI report sinks payment and software stocks Gold prices rise as Trump tariff turmoil boost safe haven demand These 2 chip stocks are new Top Picks at Citi Dow slides 700 points on Trump tariff turmoil, Nasdaq falls on AI research report (South Africa Philippines Nigeria) Morgan Stanley reiterates Overweight on Gilead stock after Arcellx deal By Investing.com Analyst Ratings Published 02/23/2026, 01:19 PM Morgan Stanley reiterates Overweight on Gilead stock after Arcellx deal 0 GILD -1.09% ACLX 77.52% Investing.com - Morgan Stanley reiterated an Overweight rating and $171.00 price target on Gilead Sciences (NASDAQ:GILD) following the company’s acquisition announcement. Gilead Sciences entered into a definitive agreement to acquire Arcellx for an implied equity value of $7.8 billion. The terms include $115 per share in cash at closing and one contingent value right of $5 per share upon achievement of cumulative global net sales of anito-cel of at least $6 billion from launch through year-end 2029. Gilead owns approximately 11.5% of Arcellx ’s outstanding common stock.The biotechnology giant, with a market capitalization of $185.92 billion, enters this acquisition from a position of financial strength. According to InvestingPro data, Gilead maintains a perfect Piotroski Score of 9 and an overall financial health rating of "GREAT," reflecting robust operational efficiency and balance sheet quality. The acquisition gives Gilead full worldwide rights to anito-cel, a BCMA-CAR-T therapy under FDA review for late-stage multiple myeloma. Gilead previously held economics of 50% of net profit in the U.S. and net profit outside the U.S. excluding low- to mid-teens percentage royalties to Arcellx. The deal removes up to $1.5 billion of potential future development and regulatory milestones that Gilead could have owed Arcellx. The FDA accepted the biologics license application for anito-cel in fourth-line or later...
Read full article at source